Cargando…
Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector
One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vect...
Autores principales: | Becker, Pamela S., Taylor, Jason A., Trobridge, Grant D., Zhao, Xin, Beard, Brian C, Chien, Sylvia, Adair, Jennifer, Kohn, Donald B., Wagner, John E., Shimamura, Akiko, Kiem, Hans-Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927804/ https://www.ncbi.nlm.nih.gov/pubmed/20485382 http://dx.doi.org/10.1038/gt.2010.62 |
Ejemplares similares
-
Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector
por: Chakkaramakkil Verghese, Santhosh, et al.
Publicado: (2016) -
Novel lineage depletion preserves autologous blood stem cells for
gene therapy of Fanconi anemia complementation group A
por: Adair, Jennifer E., et al.
Publicado: (2018) -
Large Animal Models for Foamy Virus Vector Gene Therapy
por: Trobridge, Grant D., et al.
Publicado: (2012) -
Identification of the Fanconi Anemia Complementation Group I Gene, FANCI
por: Dorsman, Josephine C., et al.
Publicado: (2007) -
Fanconi Anemia complementation group C protein in metabolic disorders
por: Nepal, Manoj, et al.
Publicado: (2018)